Clinical Trial

Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively collect clinical data from patients who underwent partial hepatectomy at Beijing Tsinghua Changgung Hospital between September 2021 and March 2025. Additionally, clinical information and liver blood samples from patients scheduled for partial hepatectomy from April 2025 onward will be prospectively collected. These samples will include normal liver tissue from the resected portion, as well as 5 mL of venous blood obtained before and after surgery. The investigators will compare the severity of hepatic IRI, the expression of macrophage polarization-related proteins, and macrophage polarization markers in blood samples between NAFLD patients and controls. The study aims to determine whether NAFLD patients experience more severe hepatic IRI and to elucidate the role and mechanisms of macrophage polarization in this context. The findings will provide a theoretical basis for understanding the molecular mechanisms underlying hepatic IRI in NAFLD patients, thereby identifying potential therapeutic targets to prevent IRI and improve prognosis in NAFLD patients undergoing partial hepatectomy.
Trial Details
NCT Number NCT06950710
Lead Sponsor Zhifeng Gao
Conditions Hepatic Ischemia-reperfusion Injury, Non-alcoholic Fatty Liver Disease
Enrollment 300 participants
Start Date 2025-04-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-30